Biomarin Pharmaceutical (BMRN)

Add to Watchlists
Create an Alert
92.49 +4.21  +4.77% NASDAQ May 25, 20:00 Delayed 2m USD

Biomarin Pharmaceutical Research and Development Expense (Quarterly):

183.95M for March 31, 2018
View 4,000+ financial data types
View Full Chart

Biomarin Pharmaceutical Research and Development Expense (Quarterly) Chart

Export Data
Save Image
Print Image

Biomarin Pharmaceutical Historical Research and Development Expense (Quarterly) Data

View and export this data going back to 1999. Start your Free Trial
Export Data Date Range:
Data for this Date Range  
March 31, 2018 183.95M
Dec. 31, 2017 168.61M
Sept. 30, 2017 154.10M
June 30, 2017 143.04M
March 31, 2017 145.00M
Dec. 31, 2016 175.24M
Sept. 30, 2016 160.83M
June 30, 2016 167.04M
March 31, 2016 158.79M
Dec. 31, 2015 176.12M
Sept. 30, 2015 158.71M
June 30, 2015 157.90M
March 31, 2015 142.07M
Dec. 31, 2014 142.07M
Sept. 30, 2014 125.69M
June 30, 2014 107.70M
March 31, 2014 86.17M
Dec. 31, 2013 97.31M
Sept. 30, 2013 88.06M
June 30, 2013 85.66M
March 31, 2013 83.74M
Dec. 31, 2012 84.36M
Sept. 30, 2012 66.21M
June 30, 2012 77.81M
March 31, 2012 73.83M
Dec. 31, 2011 57.91M
Sept. 30, 2011 58.58M
June 30, 2011 52.91M
March 31, 2011 45.02M
Dec. 31, 2010 42.20M
Sept. 30, 2010 39.37M
June 30, 2010 35.65M
March 31, 2010 30.10M
Dec. 31, 2009 27.44M
Sept. 30, 2009 26.99M
June 30, 2009 26.32M
March 31, 2009 34.36M
Dec. 31, 2008 25.73M
Sept. 30, 2008 26.18M
June 30, 2008 23.76M
March 31, 2008 17.63M
Dec. 31, 2007 24.02M
Sept. 30, 2007 17.24M
June 30, 2007 19.19M
March 31, 2007 18.16M
Dec. 31, 2006 20.57M
Sept. 30, 2006 18.10M
June 30, 2006 15.78M
March 31, 2006 12.28M
Dec. 31, 2005 12.68M

There is no data for the selected date range.

An error occurred. Please try again by refreshing your browser or contact us with details of your problem.

About R&D Expense

R&D expenses are a line item from many companies' income statements.

R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More


BMRN Research and Development Expense (Quarterly) Benchmarks

Alexion Pharmaceuticals 176.60M
Vertex Pharmaceuticals 310.55M
Ionis Pharmaceuticals 104.07M

BMRN Research and Development Expense (Quarterly) Range, Past 5 Years

Minimum 85.66M Jun 2013
Maximum 183.95M Mar 2018
Average 141.20M

BMRN Research and Development Expense (Quarterly) Excel Add-In Codes

  • Metric Code: r_and_d_expense
  • Latest data point: =YCP("BMRN", "r_and_d_expense")
  • Last 5 data points: =YCS("BMRN", "r_and_d_expense", -4)

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.




Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{}} No credit card required.

Already a subscriber? Sign in.